BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
MindMaze Therapeutics Holding SA MMTZF
3 fiscal years on record · CHF · FY2023 reported · SEC filings only
Growth
CHF 6.3M
Revenue, FY2023 · full 3-year series below
Revenue CHF M
Net income CHF M
FY2023 · Revenue 6.3 · Net income -98.2
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−1552 cents
lost on every revenue dollar
Operating margin
Net margin
FY2023 · Operating -1751.4% · Net -1551.5%
ROE
Not available in our data for this period.
The 3-year record
3 fiscal years
Every figure from documents filed with the SEC · CHF
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue CHF B | 0.0 | 0.0 | 0.0 |
| Operating income CHF B | −0.1 | −0.1 | −0.0 |
| EBITDA CHF B | −0.1 | −0.0 | −0.0 |
| Income tax CHF B | −0.0 | −0.0 | −0.0 |
| Net income CHF B | −0.1 | −0.1 | −0.0 |
| Free cash flow CHF B | −0.0 | −0.0 | −0.0 |
| EPS, diluted CHF | −8.35 | −4.80 | −0.01 |
| Dividend / sh CHF | · | · | · |
| Payout % | · | · | · |
| ROE % | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 12 reconciliationsAUDITED
Reconciled in 3 of 19 fiscal years. 64 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inoutside the United States — SEC code V8
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2021